Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities

November 20, 2013 updated by: Grazielle Vilas Boas Huguenin, Universidade Federal do Rio de Janeiro

Effect of Brazil Nut Consumption in the Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities in Hypertensive and Dyslipidemic Subjects

The purpose this research is to check the effect of Brazil Nuts consumption in oxidative stress, metabolic abnormalities and microvascular endothelial function dyslipidemic and hypertensive patients.

Study Overview

Study Type

Interventional

Enrollment (Actual)

125

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adults > 20 years old
  • Dyslipidemic
  • Hypertensive

Exclusion Criteria:

  • Allergy to nuts
  • Consumption of nuts or vitamins/minerals supplement
  • Loss weight before the research
  • pregnancy
  • Kidney chronic disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Cassava flavored flour
The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
The Brazil nut group received 13g/day of Brazil nut flour during three months.
Experimental: Brazil nut flour
The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Antioxidant biomarker
Time Frame: Change from Baseline at 12 weeks.
Change from Baseline plasma Gluthathione Peroxidase activity (nmol/min/ml) at 12 weeks, samples were stocked at -80 degrees.
Change from Baseline at 12 weeks.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxidative stress biomarker
Time Frame: Change from Baseline at 12 weeks.
The change from baseline plasma 8-isoprostane (pg/ml) at 12 weeks, samples were stocked at -80 degrees.
Change from Baseline at 12 weeks.
microvascular endothelial function
Time Frame: Change from baseline at 12 weeks
Microvascular reactivity was evaluated using an Laser Speckle Contrast Imaging system with a laser wavelength of 785 nm in combination with the iontophoresis (increasing anodal currents of 30, 60, 90, 120, 150 and 180μA for 10 second intervals spaced 1 minute apart) of acetylcholine (2% v/v) for the noninvasive and continuous measurement of cutaneous microvascular perfusion changes measured in arbitrary perfusion units.
Change from baseline at 12 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anthropometric measures
Time Frame: Change from baseline at 12 weeks
body weight (kg), body mass index (kg/m2) and waist circumference (cm).
Change from baseline at 12 weeks
Blood lipids
Time Frame: Change from baseline at 12 weeks
total Cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl) and triglycerides (mg/dl).
Change from baseline at 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Grazielle V B Huguenin, Nutricionist, Universidade Federal do Rio de Janeiro

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2011

Primary Completion (Actual)

April 1, 2013

Study Completion (Actual)

April 1, 2013

Study Registration Dates

First Submitted

November 10, 2013

First Submitted That Met QC Criteria

November 14, 2013

First Posted (Estimate)

November 21, 2013

Study Record Updates

Last Update Posted (Estimate)

November 25, 2013

Last Update Submitted That Met QC Criteria

November 20, 2013

Last Verified

November 1, 2013

More Information

Terms related to this study

Other Study ID Numbers

  • 0008.0.197.185-11
  • U1111-1132-2061 (Other Identifier: Universal trial number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyslipidemia

Clinical Trials on Brazil nut flour

3
Subscribe